DiaSorin

DiaSorin focuses its efforts to 8 fields of immunodiagnostics: Infectious diseases, Bone and Mineral, Endocrinology, Hypertension, Oncology, Gastro-Intestinal infections, Autoimmunity and Brain and Cardiac markers.

The company is also active in molecular diagnostics for infectious diseases and for the detection of some forms of leukemia.[2]

DiaSorin develops, manufactures and markets tests for the diagnosis of infectious diseases or hormonal disorders. The diagnostic tests are aimed at both private and hospital analysis laboratories worldwide, in immunodiagnostics and molecular diagnostics markets.

In immunodiagnostics, DiaSorin offers the market proprietary-based platforms on the CLIA (Chemiluminescence) and ELISA (Colorimetry) technologies.

In molecular diagnostics, DiaSorin offers the market diversified proprietary platforms based on the 3 phases of the detection process: extraction, amplification and diagnosis.[3]

The origins of the company date back to 1968, when near Vercelli on an initiative of Fiat and Montecatini, the "Sorin Biomedica" was founded by the "Società Ricerche Impianti Nucleari - Sorin".[4] In 1997 the Company acquired control of American Incstar Inc., and part of its operations were later sold to American Standard Inc.[4] DiaSorin was founded in 2000, through a management buyout operation led by the Italians Carlo Rosa and Gustavo Denegri.[5]

In 2002 DiaSorin acquired BYC Sangtec and the rights to the LIAISON platform. The commercial expansion led to the opening of new branches in Mexico, Israel, and China. The LIAISON portfolio was enriched with products for new and clinical specialty areas. In the same year the Group started the conversion of the tests previously developed with ELISA technology on the most recent and automated CLIA.[4]

In July 19, 2007 the DiaSorin title debuted at Borsa Italiana Stock Exchange.[6]

In 2014 the company obtained the approval of Hepatitis, Retrovirus tests in China; in the same year, DiaSorin launched new tests to detect leukemias. DiaSorin Group signed an agreement in 2015 with Beckman Coulter for the commercialization in China of DiaSorin Hepatitis and HIV tests.[7]

In 2016, the group acquired of Focus Diagnostics’ business unit, enabling the Group to expand its activities in molecular diagnostics.[8][9]

In 2017, a partnership with Qiagen offered an automated solution for detection of tuberculosis with QuantiFERON-TB Gold Plus available on the LIAISON analyzers. That was also the year of the Siemens Healthineers ELISA business acquisition.[10]

In October 2018 the Saluggia branch began a partnership with Meridian for the distribution of a Helicobacter pylori detection test in the United States and United Kingdom. The companies have put in place a framenwork under which they may work together on the development of new tests and products.[11]

In 2019 the commercial launch of LIAISON® XS Approval of Latent Tuberculosis Test in the United States.[12]

In February and March 2020, from the novel coronavirus pandemia, DiaSorin has devised and developed a molecular diagnostic test intended to detect all the currently known variants of the COVID-19.  The test enables sample-to-answer results within less than 60 minutes compared to the 5–7 hours currently necessary to report patient results.[13]

On 7 April 2020, DiaSorin announces the development of a new IgG CLIA test to identify antibodies against SARS-CoV-2 antibody test, that allows to detect antibodies directed against the virus in patients’ sera samples, identifying subjects who have developed an immune response to the virus, offering a tool for epidemiologic assessment of populations.[14]

On 25 April 2020, DiaSorin received Emergency Use Authorization from the U.S. Food and Drug Administration for a new serologic test for Covid-19[15].

DiaSorin is listed since 2007 in the Italian Stock Exchange and today in the FTSE Italy Mid Cap Index.